Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson’s Disease
Cells · 2024
DOI: 10.3390/cells13141214 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Woong Choi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Korea University College of Medicine, Seoul 02841, Republic of Korea. Hauptthemen laut MEDLINE: Hepatolenticular Degeneration, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 310 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Bio & Medical Technology Development Program of the National Research Foundation (NRF) of Korea, Bio & Medical Technology Development Program of the National Research Foundation (NRF) of Korea.
Abstract (Originalsprache)
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) system continues to evolve, thereby enabling more precise detection and repair of mutagenesis. The development of CRISPR/Cas-based diagnosis holds promise for high-throughput, cost-effective, and portable nucleic acid screening and genetic disease diagnosis. In addition, advancements in transportation strategies such as adeno-associated virus (AAV), lentiviral vectors, nanoparticles, and virus-like vectors (VLPs) offer synergistic insights for gene therapeutics in vivo. Wilson’s disease (WD), a copper metabolism disorder, is primarily caused by mutations in the ATPase copper transporting beta (ATP7B) gene. The condition is associated with the accumulation of copper in the body, leading to irreversible damage to various organs, including the liver, nervous system, kidneys, and eyes. However, the heterogeneous nature and individualized presentation of physical and neurological symptoms in WD patients pose significant challenges to accurate diagnosis. Furthermore, patients must consume copper-chelating medication throughout their lifetime. Herein, we provide a detailed description of WD and review the application of novel CRISPR-based strategies for its diagnosis and treatment, along with the challenges that need to be overcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Korea University College of Medicine, Seoul 02841, Republic of Korea.
- Neuroscience Research Institute, Korea University College of Medicine, Seoul 02841, Republic of Korea.
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Republic of Korea.
ORCID-Profile: Seongkwang Cha, Kyoungmi Kim
Förderung
- The Bio & Medical Technology Development Program of the National Research Foundation (NRF) of Korea
- Bio & Medical Technology Development Program of the National Research Foundation (NRF) of Korea
Zitieren
APA
Choi, W., Cha, S., & Kim, K. (2024). Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson’s Disease. Cells. https://doi.org/10.3390/cells13141214
Vancouver
Choi W, Cha S, Kim K. Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson’s Disease. Cells. 2024. doi:10.3390/cells13141214
BibTeX
@article{Choi2024,
author = {Choi, Woong and Cha, Seongkwang and Kim, Kyoungmi},
title = {Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson’s Disease},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13141214}
}
EUVIMED